Previous Article | Next Article 
Journal of Virology, April 2001, p. 3077-3088, Vol. 75, No. 7
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.7.3077-3088.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Herpes Simplex Virus-Induced Keratitis: Evaluation
of the Role of Molecular Mimicry in Lesion Pathogenesis
Shilpa P.
Deshpande,1
Sujin
Lee,1
Mei
Zheng,1
Byeongwoon
Song,2
David
Knipe,2
Judith A.
Kapp,3 and
Barry T.
Rouse1,*
Department of Microbiology, University of
Tennessee, Knoxville, Tennessee 379961;
Department of Microbiology and Molecular Genetics, Harvard
Medical School, Boston, Massachusetts 021152;
and Departments of Pathology and Ophthalmology and Winship
Cancer Center, Emory University School of Medicine, Atlanta, Georgia
303223
Received 10 October 2000/Accepted 24 December 2000
 |
ABSTRACT |
Viruses are suspected but usually unproven triggering factors in
autoimmunity. One favored mechanism to explain the role of viruses in
the genesis of autoimmunity is molecular mimicry. An immunoinflammatory
blinding lesion called herpetic stromal keratitis (HSK) that follows
ocular infection with herpes simplex virus (HSV) is suggested to result
from a CD4+ T-cell response to a UL6 peptide of HSV that
cross-reacts with a corneal autopeptide shared with the immunoglobulin
G2ab (IgG2ab) isotype. The present report
reevaluates the molecular mimicry hypothesis to explain HSK
pathogenesis. Our results failed to reveal cross-reactivity between the
UL6 and IgG2ab peptides or between peptide reactive T cells
and HSV antigens. More importantly, animals infected with HSV failed to
develop responses that reacted with either peptide, and infection with a recombinant vaccinia UL6 vector failed to cause HSK, in spite of
generating UL6 reactivity. Other lines of evidence also failed to
support the molecular mimicry hypothesis, such as the failure to affect
HSK severity upon tolerization of susceptible BALB/c and
B-cell-deficient mice with IgG2ab or UL6 peptides. An
additional study system revealed that HSK could be induced in mouse
strains, such as the OT2 × RAG1
/
mice (T cell
receptor transgenic recognizing OVA323-339) that were
unable to produce CD4+ T-cell responses to any detectable
HSV antigens. Our results cast doubt on the molecular mimicry
hypothesis as an explanation for the pathogenesis of HSK and indicate
that if autoimmunity is involved its likely proceeds via a bystander
activation mechanism.
 |
INTRODUCTION |
That autoimmune diseases result from
virus infection is an attractive hypothesis, but it has yet to be
proven, at least for any human autoimmune syndrome (39).
However, several animal models clearly link viruses and autoimmunity
(11, 19, 25, 38, 40), although the mechanisms by which
viruses trigger autoreactivity remain uncertain. The explanations for
this include molecular mimicry and bystander activation (12,
39). The latter represents a complex which could include the
release of normally sequestered antigens from damaged cells that now
become immunogenic, alteration of host protein structure
(27), and the subversion of host cells, causing
proinflammatory mediator production or the synthesis of abnormal
products such as autoantibodies (39). The more simple and
perhaps most appealing idea to explain the genesis of virus-induced
autoimmunity is molecular mimicry (19). This suggests that
causative viruses express epitopes that cross-react with a host protein
and that the initial immune response to viruses carries over to include
anti-host reactivity (40). Proving unequivocally the
molecular mimicry hypothesis in any model has been difficult (39).
One model advocated to support the molecular mimicry hypothesis is a
blinding inflammatory reaction in the cornea set off by infection with
herpes simplex virus (HSV). This lesion, termed herpetic stromal
keratitis (HSK), is orchestrated by CD4+ T cells that are
suggested to recognize autoantigens in the cornea (31,
36). One such autoantigen may be a 16 amino acid peptide shared
by the immunoglobulin G2ab (IgG2ab) isotype
(2). A peptide of almost identical amino acid sequence is
found in the UL6 protein of HSV, and this has been advocated as the
molecular mimic which elicits the HSK syndrome (41). Supporting the corneal autoantigen hypothesis is the observation that
mice such as C57BL/6 (B6) and CB.17, which express the
Ig2ab isotype and so are immunologically tolerant to the
autoantigen, are highly resistant to HSK development (2, 21,
35). In addition, viral mutants that lack the mimicking peptide
fail to induce HSK in susceptible mouse strains and lesions can be
adoptively transferred to virus-infected nude mice with UL6 and IgG2a
immune T cells (2, 41). Accordingly, the case for HSK
representing an autoimmune reaction set off by a virus that acts as a
molecular mimic appears persuasive.
In the present report, we readdress the role of autoimmunity and
molecular mimicry between IgG2a and UL6 peptides in HSK pathogenesis by
using a mouse model involving different mice strains on the same
genetic background as used in the previous reports and a strain of HSV
type 1 (HSV-1) (strain RE) usually used for the induction of HSK
lesions. Mice strains used in the study included susceptible BALB/c
(B/c) mice, resistant B6 mice, and B6 µ-chain knockout (Bk/o) mice.
The latter do not produce immunoglobulin (Ig) and therefore would lack
tolerance to the corneal autoantigen shared with the IgG2ab
isotype. Several observations failed to support the molecular mimicry
hypothesis. First, analysis of in vivo delayed-type hypersensitivity (DTH) reactions and in vitro T-cell responses of draining lymph node
and splenocytes revealed none of the expected cross-reactivities. Accordingly, mice ocularly infected with HSV failed to generate demonstrable in vivo and in vitro responses to either the UL6 or
IgG2ab peptides. Second, although infection with
recombinant vaccinia virus expressing the UL6 protein induced T cells
that reacted with the UL6 peptide, neither cross-reactivity with the
IgG2ab peptide nor cross-reactivity with HSV could be
demonstrated. Moreover, mice immunized with either UL6 or
IgG2ab peptides elicited T cells that reacted only with
homologous peptides. Third, attempts to change the susceptibility of
B/c or Bk/o mice by tolerizing them to the UL6 or IgG2ab
peptides prior to HSV infection failed to significantly affect their
HSK susceptibility status. Fourth, adoptive transfer of HSV immune
CD4+ T cells to SCID mice later infected with
replication-defective mutants, which were either UL6 positive or
negative, both failed to yield HSK. Finally, we demonstrated that
OT2 × RAG1
/
(OT2xRAG1
/
) mice,
which are T cell transgenic to recognize an OVA peptide, still develop
HSK; yet such mice failed to recognize any HSV antigens. Although our
results cannot exclude autoreactivity as being involved in the
pathogenesis of HSK, taken together, they provide no support that the
UL6 protein or any other protein of HSV provides a molecular mimic
which induced molecular mimicry. Rather, our results indicate that HSV
represents an immunoinflammatory reaction which, if in part autoimmune,
involves a bystander activation mechanism.
 |
MATERIALS AND METHODS |
Mice.
B/c mice and B6 mice (4 to 6 weeks old) were purchased
from Harlan Sprague-Dawley (Indianapolis, Ind.). B-cell-deficient mice (Bk/o, H-2b-background), made by targeted
disruption of the membrane exon of the Ig µ-chain gene
(13) were kindly provided by H. W. Virgin (Washington
University School of Medicine, St. Louis, Mo.).
OT2xRAG1
/
mice were kindly provided by J. Kapp (Emory
University, Atlanta, Ga.) (22). BALB/c SCID mice (Taconic
Farms, Germantown, N.Y.) were bred in the specific-pathogen-free
facility. All manipulations involving the SCID and
RAG1
/
mice were performed in a laminar flow hood. To
prevent bacterial superinfections, all SCID and RAG1
/
mice received prophylactic treatment of a Sulfatrim pediatric suspension (Barre-National, Baltimore, Md.) at the rate of 5 ml per 200 ml of drinking water. All experimental procedures were in complete
agreement with the Association for Research in Vision and Ophthalmology
resolution on the use of animals in research.
Virus and reagents.
The HSV-1 RE and HSV-1 KOS strains were
propagated and titrated on monolayers of Vero cells (ATCC CCL81) by
using standard protocols (30). All virus stocks were
separated into aliquots and stored at
80°C. Vaccinia virus
expressing UL6 was kindly provided by A. H. Patel (Glasgow
University, Glasgow, United Kingdom). The ICP8
/
HSV-1
KOS mutant was kindly provided by D. Knipe (Harvard University, Boston,
Mass.), and the ICP 4
/
HSV-1 KOS mutant was from J. C. Glorioso (University of Pittsburgh, Pittsburgh, Pa.). UL6
(299-314), IgG2a (292-308), and
hemagglutinin (HA) peptides were synthesized by Genemed Synthesis,
Inc., South San Francisco, Calif.
Corneal HSV infections and clinical observations.
Corneal
infections of all mice groups were conducted under deep anesthesia
induced by the inhalant anesthetic methoxyfurane (Metofane; Pittman
Moore, Mondelein, Ill.). Mice were scarified on their corneas with a
27-gauge needle, and a 4-µl drop containing the required viral dose
was applied to the eye and gently massaged with the eyelids. The eyes
were examined on different days postinfection with a slit lamp
biomicroscope (Kowa Co., Nagoya, Japan), and the clinical severity of
the keratitis of individually scored mice was recorded. The scoring
system was as follows: +1, mild corneal haze; +2, moderate corneal
opacity or scarring; +3, severe corneal opacity, but iris visible; +4,
opaque cornea, iris not visible; and +5, necrotizing stromal keratitis.
Virus recovery and titrations.
At various time points
postinfection, swabs of the corneal surface were obtained. The swabs
were put into sterile tubes containing 500 µl of Dulbecco modified
Eagle medium (DMEM) with 100 IU of penicillin and 100 µg of
streptomycin (Life Technologies, Grand Island, N.Y.) per ml and then
stored at
80°C. For the detection and quantification of HSV in the
swabs, the samples were thawed and vortexed. Duplicate 200-µl
aliquots of each sample of thawed swab media were plated on Vero cells
grown to confluence in 24-well plates at 37°C in 5% CO2
for 1 h and 30 min. Medium was aspirated, and 1 ml of 2× DMEM
containing 1% low-melting-point agarose was added to each well.
Cultures were observed daily for the development of typical cytopathic
effect. The titers were calculated as the PFU according to the standard
protocol (30).
Analysis of viral expression of UL6 protein.
HEp-2 cells
were infected with the indicated viruses at a multiplicity of infection
(MOI) of 20.0 or were mock infected. At 12 h postinfection, total
cell extracts were prepared, and proteins were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis in a 9% DATD
(N, N'-diallyltartardiamide)-cross-linked sodium dodecyl sulfate-gel, transferred by electroblotting, and processed for
immunoblotting using rabbit polyclonal anti-UL6 antibody (1:500 dilution) kindly provided by Joel Baines (33) and
secondary antibody, followed by visualization as described previously
(29).
DTH.
At day 10 post-virus infection on scarified corneas of
mice or with peptide immunization in complete Freund adjuvant (CFA), test antigens in 20 µl of phosphate-buffered saline (PBS) were injected in the left ear pinna of anesthetized mice, and PBS diluent (peptide-specific DTH reaction) or Vero cell extract (HSV-specific DTH
reaction) was injected in the right ear, respectively. Ear thickness
was measured 48 h postinjection with a screw gauge meter (Oditest;
H. C. Kroeplin GhBH, Schluechtern, Germany) as described elsewhere
(14). The test antigens used were 20 µl of
UV-inactivated HSV-1 KOS (105 PFU prior to UV inactivation)
or 10 µg of peptides per ml. The mean increase between the thickness
of the left and right ear was calculated and is expressed in
10
2 mm.
Lymphoproliferation assay.
To test antigen-specific T-cell
responses, individual spleens and cervical and mandibular lymph nodes
were used as responders for lymphoproliferation assays stimulated with
enriched dendritic-cell populations obtained by the method of Nair et
al. (18). Briefly, these responders were restimulated in
vitro with irradiated syngeneic dendritic cells infected with UV HSV-1
KOS (MOI = 5.0) or pulsed with peptides at various concentrations
or with irradiated naive dendritic cells and then incubated for 4 days
at 37°C for peptide stimulation or for 5 days for HSV-1 stimulation.
At 18 h before harvesting, [3H]thymidine (1.0 µCi/well) was added to all culture wells, and the plates were read
using a
-scintillation counter (Trace 96; Inotech, Lansing, Mich.).
The results were expressed as mean counts per minute (cpm) ± the
standard deviation.
Quantification of IFN-
production by ELISA.
To assay for
gamma interferon (IFN-
) production, 2 × 106
splenocytes per ml were stimulated in vitro with 5 µg of peptide or
UV-inactivated virus-pulsed irradiated syngeneic antigen-presenting cells per ml. Supernatants were collected at 48 h for concanavalin A (ConA) stimulation (5 µg/ml), at 72 h for peptide stimulation (5 µg/ml), or at 96 h for UV-inactivated HSV-1 (MOI = 5.0) or vaccinia virus (MOI = 5.0) stimulation and then screened for the presence of IFN-
by enzyme-linked immunosorbent assay (ELISA) as
described previously (5).
Histopathology and immunohistochemical staining.
Eyes were
enucleated and fixed in 10% buffered neutral formalin and embedded in
paraffin as described previously (35). Sections (5 µm
thick) were cut and stained with hematoxylin and eosin. For
immunohistochemistry, eyes were frozen in optimum cutting temperature
(OCT) compound (Miles, Elkart, Ind.). The sections (5 µm thick) were
cut, air dried, and fixed in cold acetone for 5 min. The sections were
then blocked with heat-inactivated rabbit serum (Sigma) and stained for
the presence of HSV antigens by the use of rabbit anti-HSV antiserum
(Dako Corp., Carpinteria, Calif.), which was followed by treatment with
biotinylated anti-rabbit antibody (1/20 dilution; Biogenex, San Ramon,
Calif.). Alternatively, sections were stained with biotinylated
anti-CD4 or anti-KJ1-26.1 antibody (biotinylated
anti-OVA-TCR, a kind gift from Jerold Woodward, University of Kentucky, Lexington, Ky.). Sections were treated with
horseradish peroxidase-conjugated streptavidin (1/1,000 dilution; Jackson Immunoresearch Laboratories, Inc.) and 3,3'-diaminobenzidine substrate (Biogenex, San Ramon, Calif.) and then counterstained with
hematoxylin. For OVA-TCR (KJ1-26.1) staining, sections were pretreated
with a tyramide signal amplification kit (TSA Indirect; Dupont NEN,
Boston, Mass.) before treatment with diaminobenzidine.
Flow cytometry.
Cervical lymph node cells were analyzed for
the cell surface expression of activation markers. Viable cells were
blocked with heat-inactivated fetal bovine serum and washed with flow
cytometry buffer (1× PBS with 1% bovine serum albumin and 0.05%
sodium azide). Cells were double stained with anti-CD4-FITC
(Pharmingen) and anti-CD44-PE (Pharmingen) or with anti-CD62L-PE
(Pharmingen) and anti-CD45RB-RPE (Calbiochem). Events were recorded
with FACSCALIBUR (Becton Dickson, San Jose, Calif.) and analyzed using
Cellquest 3.0 version (Becton Dickson).
Statistical analysis.
Wherever specified, the data obtained
were analyzed for statistical significance by using the Student's
t test.
 |
RESULTS |
Analyses of cross-reactivity of Ig peptide and UL6 peptide of HSV
in B/c and B6 mice.
Previous reports indicate that HSK in a
susceptible mouse strain represents an immune response against a
peptide derived from the UL6 protein of HSV that cross-reacts with a
corneal autoantigen that forms part of the IgG2ab (amino
acids 292 to 308) Ig isotype encoded by the IgHb locus
(2). This latter peptide is referred to as G2a. If the UL6
peptide acts as a molecular mimic of G2a and is indeed involved in the
pathogenesis, then HSV ocular infection would be expected to induce
T-cell responses in recipient animals that react with both the UL6 and
the G2a peptides. To test these ideas, groups of susceptible B/c and
resistant B6 mice were infected on scarified corneas with HSV or were
immunized systemically with either the UL6 or G2a peptides emulsified
in CFA. The resultant pattern of reactivity was measured. By 10 days
postinfection HSV-infected B/c mice showed signs of HSK which gradually
increased in severity over the next 2 weeks (data not shown). In
contrast, under the same infection conditions B6 mice showed none or
extremely mild signs of HSK (data not shown). However, with regard to
antigen-specific immune reactivity, several points are recorded in Fig.
1 and Table 1. First, HSV infection of both mouse
strains resulted in T-cell responses reactive to virus detectable in
vivo by the DTH reaction (Fig. 1A and B) or in vitro in lymphoid
tissues by specific lymphoproliferation (Fig. 1C and D) or cytokine
release (Table 1). However, neither B/c nor B6 mice showed detectable
cross-reactivity against either the UL6 or G2a peptides. It was
evident, nevertheless, that both the UL6 and G2a peptides were
immunogenic in B/c mice, but the responses detected were neither
mutually cross-reactive nor reactive in vitro with HSV-1.
Interestingly, the UL6 peptide was not as immunogenic as the G2a
peptide in the B/c mice strain. Furthermore, as expected, the G2a
peptide was not immunogenic in the B6 strain in which it is a
self-peptide.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 1.
Analyses of cross-reactivity between G2a peptide, UL6
peptide, and HSV in lymphoid cells following peptide immunization or
HSV-1 RE ocular infection. Groups of B/c and B6 mice were immunized
subcutaneously with 100 µg of peptide in CFA at the base of neck or
were infected with 5 × 105 PFU or 107 PFU
of HSV-1 RE, respectively, on scarified corneas. (A and B) At day 15 postinfection, a DTH reaction was elicited in the ear pinnae of mice to
10 µg of peptides per ml or UV-inactivated HSV-1 (105
PFU) and 1× PBS or Vero extract in a 20-µl volume in the right and
left ear pinnae, respectively. The increase in the ear thickness was
measured after 48 h as described in Materials and Methods. The
data are expressed as the difference in ear thickness ± the
standard deviation (in mm 2) and represents the mean of
two experiments, each including six to seven mice. Statistically
significant differences between groups (**, P < 0.001) and within groups (*, P < 0.05) are
indicated. (C and D) At days 9 to 15 post-peptide immunization and at
days 15 to 18 post-HSV-1 ocular infection, mice (n = 4)
were sacrificed, and cervical and submandibular DLN or spleen cells
were used as responders in a lymphoproliferation assay as described in
Materials and Methods. Responders were stimulated with irradiated
syngeneic splenocytes pulsed with a range of peptide concentrations
(10, 1.0, and 0.1 µg/ml), UV-irradiated virus (MOI = 5.0), or no
stimulation. Data are represented only for peptide stimulations with a
10-µg/ml concentration. Polyclonal stimulator, ConA (2 µg/ml), was
used as a positive control (data not shown). Results are the mean of
three independent experiments. The experiment was repeated at least six
times with similar results. Statistically significant differences
between HSV-stimulated responders and peptide-stimulated responders
(*, P < 0.0001; **, P < 0.05)
are indicated.
|
|
These results fail to support molecular mimicry and indicate that the
UL6 protein of HSV fails to induce detectable UL6 peptide-specific
responses in lymphoid tissue following ocular infection. However,
to
further examine a possible role of UL6 in HSK, B/c mice were
ocularly
infected with a recombinant vaccinia virus expressing
the UL6 protein
(kindly provided by A. H. Patel). This infection
failed to cause
lesions typical of HSK (data not shown), but analysis
of DLN at 14 days
postinfection revealed UL6 peptide-specific
T cells detectable by
proliferation (Fig.
2A) or IFN-

cytokine
release assay (Fig.
2B). Nevertheless, the same population
failed
to react with the G2a peptide or to stimulation with HSV
antigen.
Taken together, the data indicate that the UL6 protein in HSV
infections is not a strong immunogen. Immune reactivity against
UL6,
however, can be detected only under ideal circumstances,
such as when
administered with adjuvant or in the form of vaccinia
virus expressing
UL6 protein.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 2.
Recombinant vaccinia virus expressing UL6 protein fails
to induce reactivity to HSV or G2a peptide. Groups of B/c mice
(n = 6) were infected with 2 × 106
PFU of vaccinia virus expressing UL6 (Vac UL6) on scarified corneas. At
day 14 postinfection mice were sacrificed, and pooled popliteal lymph
nodes and individual splenocytes were used as responders in a
lymphoproliferation assay (A) and an IFN- cytokine ELISA (B) as
described in Materials and Methods. Responders were stimulated with
irradiated syngeneic splenocytes pulsed with UV-irradiated vaccinia
virus (MOI = 5.0), UV-irradiated HSV (MOI = 5.0), and the
UL6, G2a, and HA peptides (10, 1.0, and 0.1 µg/ml). The data
represent peptide stimulation with a 10-µg/ml concentration. The
polyclonal stimulator, ConA (2 µg/ml), was used as a positive control
(data not shown). The results of two independent experiments are
expressed as the means ± the standard deviations. Statistically
significant differences within groups (**, P < 0.001) and between groups (*, P < 0.05) are
indicated.
|
|
A further experiment to test the role of a peptide derived from the UL6
protein in the pathogenesis of HSK, was to analyze
the susceptibility
of SCID mice infected with HSV or mutant viruses
and reconstituted with
CD4
+ T cells reactive to HSV. This reconstitution model
results in
HSK, provided the SCID mice are infected with wild-type HSV
(
16).
However, when reconstituted SCID mice were
repeatedly infected
at days 0, 2, and 4 with either ICP4

mutant d120, which expressed little if any UL6, or an
ICP8

mutant (which expressed UL6 at levels about
one-third that of
the wild-type virus) (Fig.
3), neither infection resulted in the
expression of HSK (Fig.
4A). However, the
infection procedure
was assumed to be immunogenic, since the recipient
mice developed
lymphadenopathy, had an increased number of activated
cells in
the draining lymph nodes (DLN) (Fig.
4B), and showed enhanced
HSV-specific lymphoproliferation responses compared to uninfected
reconstituted SCID mice (Fig.
4C) in samples tested at day 11
postinfection.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Analysis of UL6 protein expression by various HSV
strains. Infected cell lysates from Hep-2 cells infected with the
indicated viruses were analyzed for UL6 expression by Western blotting
as described in Materials and Methods. Shown in figure is the image of
Western blotting. The top band provides a loading control, and the
bottom band is the UL6 protein. Lanes: 1, mock infected; 2, KOS
wild-type (WT) virus; 3, KOS d120 (ICP4 ) virus; 4, KOS
HD-2 (ICP8 ) virus.
|
|

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 4.
Infection with replication-defective HSV (UL6 positive
or negative) fails to induce HSK in SCID mice reconstituted with HSV
immune T cells. SCID mice (n = 5/group) were
infected with ICP4 / , ICP8 / , and HSV-1
KOS (5 × 105 PFU) on scarified corneas at days 0, 2, and 4. At day 1 postinfection, SCID mice were reconstituted with
107 HSV immune splenocytes in a 400-µl volume of 1× PBS
given i.v. The data represents the results from one of two independent
experiments with similar results. (A) Mean clinical scores of SCID mice
at days 7, 9, 11, and 12 postinfection. Mice were scored by using a
slit-lamp microscope as described in Materials and Methods. (B and C)
Mice were terminated at day 13 postinfection, and cervical and
submandibular DLN cells were used as responders in an HSV-specific
lymphoproliferation assay (C) or were stained for activation markers
CD62L, CD45 RB, and CD44 by flow cytometry assay (B) as described in
Materials and Methods. The percentage of cell surface expression of
activation markers under marker M2 is indicated in the histograms. The
data indicate the presence of activated HSV-specific CD4+ T
cells in all of the wild-type and mutant virus-infected reconstituted
SCID mice groups irrespective of the development of HSK lesions shown
in panel A.
|
|
Role of the Igh-1b locus in affecting susceptibility to HSK.
The autoimmune hypothesis explaining the pathogenesis of HSK finds
support from the observation that the susceptible mouse strains develop
CD4+ T cells which recognize the G2a peptide expressed in
the damaged corneal stroma during HSK (2). Resistant
strains such as CB17 and B6 do not recognize the G2a peptide, since in
these strains the peptide is a self-component. Our data support the
observation that HSK resistant B6 mice fail to respond to G2a peptide
upon immunization in CFA (Fig. 5A). In
contrast, mice of the B6 background that lack Ig expression because of
an Ig µ-chain knockout did respond upon immunization with the G2a
peptide (Fig. 5A). Furthermore, Bk/o mice were far more susceptible to
ocular infection with HSV (Fig. 6). At
doses of virus well tolerated by B6 mice, most Bk/o animals succumbed
to viral encephalitis. At lower, nonlethal doses of HSV infection, most
Bk/o mice expressed HSK, whereas the same virus dose failed to induce
lesions in B6 mice. The observation of greater susceptibility combined
with reactivity to the G2a peptide could appear as supportive of
autoimmunity pathogenesis in HSK. However, the data in Fig. 5B cast
doubt as to any role for the G2a peptide in HSK in Bk/o mice.
Accordingly, following HSV infection of such mice, the animals failed
to develop demonstrable reactivity in the DLN to the G2a peptide nor,
in fact, to the UL6 peptide. Nevertheless, the mice did develop
reactivity to HSV.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 5.
Peptide G2a immunization or HSV infection in Bk/o fails
to generate cross-reactivity. Groups of Bk/o and B6 mice (n = 4) were infected with 107 PFU of HSV-1 RE on
scarified corneas or were immunized with 100 µg of UL6, G2a, or HA
peptides in CFA. Mice were terminated from days 9 to 15 post-peptide
immunization or days 15 to 18 post-HSV infection. DLN and spleen cells
were used in lymphoproliferation assays with various concentrations of
G2a, UL6, and HA peptides (10, 1.0, or 0.1 µg/ml; the data shown here
represent peptide stimulation with a 10-µg/ml concentration) or
UV-irradiated HSV (MOI = 5.0) as described previously. The data are
representative of one of three experiments with similar results.
Statistically significant differences between groups are indicated
(*, P < 0.001).
|
|

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 6.
Bk/o mice are highly susceptible to herpetic
encephalitis and HSK. Bk/o and B6 mice (n = 10 to 12)
were infected on scarified corneas with a range of infectious doses and
then examined for survival and induction of HSK lesions. The data
represent one of two similar experiments. (A) Lesions were scored using
a slit-lamp microscope and were recorded as described in Materials and
Methods. The data represent the percentage of mice developing lesion
scores at day 15 postinfection of 3.0. (B) Mice were examined daily
for signs of herpetic encephalitis. The results are expressed as the
percent survival of mice per time point.
|
|
To further test the putative role of the G2a peptide as the autoantigen
recognized by CD4
+ T cells in HSK-susceptible mice, the
effects of tolerization
against the peptide on the subsequent
susceptibility to ocular
infection was investigated. Should the G2a
peptide be a major
target during HSK, tolerization was expected to
diminish susceptibility
to HSK, as was indicated to occur in
susceptible CAL.20 mice tolerized
with the G2a
b protein
(
2). In our experiments, both B/c and Bk/o mice were
tolerized by exposure to high amounts of the soluble peptide,
as
described by others (
2,
41). Mice were judged to be
tolerant
based upon their subsequent response to immunization with the
G2a or UL6 peptide in CFA. As shown in Fig.
7, tolerized mice
had
markedly diminished peptide-specific proliferation and cytokine
responses compared to controls. Despite the apparent tolerization
of
both B/c and Bk/o mice, both failed to become more resistant
to HSK
compared to control animals. These data cast doubt regarding
the
contribution of the G2a peptide, at least in HSK-susceptible
B/c and B6
Bk/o mice, to HSK pathogenesis.


View larger version (86K):
[in this window]
[in a new window]
|
FIG. 7.
Tolerization of peptides fails to induce resistance to
HSK in susceptible Bk/o or B/c mice. Groups of Bk/o mice and B/c mice
(n = 12) were tolerized i.v. with 50 µg of soluble
UL6 or G2a peptides at days 0 and 7. At day 15 posttolerization, groups
of peptide tolerized mice (n = 6) were infected with
HSV-1 RE alone (tolerized) or were infected with HSV-1 RE
(107 PFU for Bk/o mice and 106 PFU for B/c
mice) on scarified corneas, as well as immunized with 100 µg of the
same peptide in CFA (control). Groups of age- and sex-matched mice
(n = 6) were immunized with 100 µg of the same
peptide in CFA and then infected with HSV-1 RE (immunized) or infected
with HSV-1 RE alone (untreated). Mice were examined for lesions by
using a slit-lamp microscope, and the mean clinical scores at days 9, 12, 15, and 21 are shown. Mice were terminated at day 18 postinfection,
and DLN cells were used in a lymphoproliferation assay to tolerogenic
peptides and in an IFN- cytokine assay to peptides and UV-irradiated
HSV (MOI = 5.0), as described previously. The data represent one
of three experiments with similar results. (A) G2a-tolerized Bk/o mice
(B) UL6-tolerized Bk/o mice (C) G2a-tolerized B/c mice. (D)
UL6-tolerized B/c mice.
|
|
An explanation for the heightened susceptibility of Bk/o mice to
HSK.
As indicated previously, Bk/o mice of the same genetic
background as B6 mice, yet lacking B cells and the ability to produce antibody, were highly susceptible to ocular infection with HSV. Although viral clearance with respect to HSV infection is usually considered principally carried out by T-cell-mediated immunity (21), the inability to generate antibody may result in a
more prolonged infection of the cornea. This was in fact the case, as
shown in Fig. 8. The duration of
detectable virus in ocular swabs was at least 4 days longer in Bk/o
mice than in B6 mice. This prolonged presence of virus could bring into
operation an additional mechanism of pathogenesis referred to as
bystander activation (6, 7). Thus, as observed previously,
T-cell-transgenic B/c mice backcrossed to SCID or RAG still develop
HSK, even though they are unable to immunologically recognize HSV
antigens (6, 7, 8). Support for the bystander mechanism to
explain the HSK pathogenesis is shown in Fig. 8. The results show HSK
following HSV infection of mice on a B6 background that were T cell
transgenic, with their CD4+ T cells recognizing the
OVA323-339 peptide. Such OT2 mice were backcrossed to
RAG
/
and so were incapable of producing Ig and
generated negative or minimal T-cell responses to antigens other that
the OVA peptide (22). Upon HSV infection of scarified
corneas, the animals developed typical HSK before dying of encephalitis
at ca. day 13 postinfection. Animals failed to express detectable
HSV-specific immune responses (Table 2)
even if animals were repeatedly immunized with UV-inactivated HSV (data
not shown). The presence of viral antigens in the corneal stroma of
such mice evident at the site of inflammation likely provides the
stimulus for bystander activation of T cells (Fig. 9B), resulting in
HSK (Fig. 9A, C, and D). Since the
OT2xRAG1
/
mice failed to develop detectable immune
responses to HSV and yet still developed HSK, as was also observed in
other strain combinations (7, 8), these data fail to
support a role for any HSV protein as providing a molecular mimic of a
corneal autoantigen involved in HSK.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 8.
Persistence of virus for longer durations in the absence
of Ig in Bk/o mice. Groups of Bk/o and B6 mice (n = 6)
were infected with 107 PFU on scarified corneas. Ocular
swabs were taken on days 0 to 10 postinfection and tested for the
presence of virus by the standard plaque assay described in Materials
and Methods. The data are represented as the means ± the standard
deviations.
|
|

View larger version (110K):
[in this window]
[in a new window]
|
FIG. 9.
Viral antigen and CD4+ KJ+ T
cells in the corneal stroma of OT2xRAG1 / HSV ocularly
infected mice. OT2xRAG1 / mice were infected with 2 × 106 PFU virus on scarified corneas. At days 10 to 13 postinfection, mice were sacrificed, and the eyes were snap-frozen in
OCT compound. (A) Histopathology of infiltrating cells in the corneal
stroma. (B) Immunohistochemistry for viral antigens in the corneal
stroma (magnification, × 200). (C and D) Immunohistochemistry for
CD4+ cells (magnification, × 400) (C) and for
OVA323-339 TCR clonotypic antibody KJ1-26.1+
cells (magnification, ×400) (D).
|
|
 |
DISCUSSION |
Viruses are suspected as triggering agents in several autoimmune
lesions with several mechanisms likely involved (39). A favored hypothesis is that viruses contain epitopes that cross-react with host proteins and that the immunity induced reacts both to virus
and to self. This molecular mimicry hypothesis arouses enthusiasm (19), but it has been difficult to prove, especially in
natural of autoimmune diseases. One animal disease model that supports molecular mimicry is HSK, a blinding immunoinflammatory reaction of the
cornea caused by HSV infection (31, 36). Molecular mimicry
in HSK is suggested to occur between the HSV-encoded protein UL6 and a
corneal autoantigen that also forms part of the IgG2ab
isotype of Ig (2, 41). The present report, however, raises doubt that molecular mimicry, at least with regard to the UL6 protein,
explains the pathogenesis of HSK. Accordingly, if a peptide derived
from an HSV protein was principally involved in driving an inflammatory
reaction, either virus induced or autoreactive, it would likely be
strongly immunogenic and induce a readily detectable immune response in
infected animals. In our studies, we failed to detect UL6
peptide-specific T-cell responses in either the DLN or splenocytes of
HSV-infected animals. Animals could process and respond to the UL6
peptide, however, since animals ocularly infected with a recombinant
vaccinia virus vector that expressed the UL6 protein generated UL6
peptide-specific T cells. Also, contrary to the molecular mimicry idea,
we were unable to detect cross-reactivity between the UL6 and G2a
peptides when DLN cells from peptide-immunized mice were analyzed for
lymphoproliferation or cytokine-producing responses in vitro.
Additionally, tolerization of susceptible recipients to either UL6 or
G2a peptides had no demonstrable effect on the nature of their HSK
lesions, and when SCID mice, reconstituted with HSV immune
CD4+ T cells, were infected with UL6+ or
UL6
HSV mutants, neither type of infection resulted in
HSK. Finally, HSK could still be induced in
OT2xRAG1
/
mice that were unable to mount detectable
immune responses against HSV antigens. Taken together, our results fail
to support a role for molecular mimicry involving HSV proteins,
and particularly UL6, in the pathogenesis of HSK. Although we cannot
exclude autoimmune events as contributing to lesion expression,
these would seem to involve mechanisms such as bystander activation
rather than molecular mimicry.
Although it is likely that infectious agents are involved in the
causation and expression of autoimmune diseases, it has been difficult
to verify this notion, especially with human autoimmune diseases
(39). The case for infectious agents as causes of some animal autoimmune diseases is stronger particularly for inflammatory demyelinating disorders. For example, both Theiler's virus and murine
corona virus appear able to cause autoreactive lesions in the central
nervous system (4, 17, 34). In these examples, the
mechanisms involved remain unresolved, but they are unlikely to involve
molecular mimicry (4, 17, 34). Another model, coxsackievirus myocarditis, it often assumed to be an autoimmune lesion
resulting from molecular mimicry (12, 20), but since the
virus persists (32) this model could represent a chronic antiviral response rather than autoreactivity (9, 23).
Similarly, coxsackievirus has been incriminated in insulin-dependent
diabetes mellitus by a molecular mimicry mechanism (1).
However, this notion has been questioned by others based on the
development of diabetes in TCR-transgenic mice that involves islet
antigens that differ from those implicated in molecular mimicry
(10).
Molecular mimicry as an inciting mechanism for autoimmunity has been
suggested for several additional rodent autoimmune-disease models, but
in almost all cases the evidence is circumstantial or unconfirmed
(39). The basis for the view that HSK is an autoreactive T-cell-mediated lesion is also largely circumstantial and derives mainly from the observation that lesions persist and may even progress
in the apparent absence of viral antigens (31, 36). The
best evidence that HSK could be an autoimmune lesion involving molecular mimicry came from an analysis of the susceptibility status of
two congenic strains of mice differing only in the IgH locus (encoding
the IgG2a isotype of Ig) (2, 41). In such studies, corneal
extracts from susceptible affected mice could stimulate T-cell clones
reactive with a 16-amino-acid peptide of IgG2ab. Moreover,
the G2a-specific T-cell clones could transfer disease to usually
resistant HSV-infected athymic mice. In addition, susceptible CAL.20
mice became resistant if tolerized with the G2a peptide prior to
infection. Subsequently, the molecular mimicry hypothesis was invoked
since a peptide in the UL6 protein shared sequence similarity with G2a
(41). In addition, lesions in susceptible mice were
reported to occur only if animals were infected with UL6+
but not with UL6
HSV mutants. Taken together, such data
make a strong case for molecular mimicry and autoimmunity in HSK.
In the present report using slightly different mouse strains but with
the same IgH locus disparities, we failed to confirm a role for a UL6
epitope in HSK. We have no explanation for our discordant results. We
reasoned that, as is noted to occur with other models that involve
molecular mimicry (19, 39), if the UL6 peptide is involved
as a molecular mimic in HSK pathogenesis it should be a potent
immunogen when the virus was used for infection. Our studies failed to
demonstrate any UL6 peptide-specific responsiveness in mice infected
with HSV, although weak though undetectable responses remain a
possibility. In addition, T cells reactive with UL6, taken from
peptide-immunized mice, neither reacted with HSV-infected cells (not
shown) or indeed the G2a peptide. Furthermore, if the UL6 peptide,
cross-reacting with G2a, accounts for the HSK lesions, one might have
expected lesions to result from ocular infection with a recombinant
vaccinia virus expressing UL6 protein (which induced UL6 peptide
reactivity). This did not occur. Finally, we consistently failed to
induce HSK in reconstituted SCID or nude (not shown) mice repeatedly
infected ocularly with mutant viruses. One of the compelling lines of
evidence that supported molecular mimicry in a previous report was that
lesions were only produced if reconstituted nude mice were subsequently
infected with mutant virus that was UL6+ but not when
infected with UL6
virus mutants. We and others
(28) found that generating HSK requires infection with
replication-competent virus (3). Recently, others have
also questioned the role of UL6 in human HSK. Thus, reactivity to UL6
protein has not been observed with T-cell clones derived from human
ocular herpetic keratitis (37), and no genetic variability
in UL6 amino acids 299 to 314 has corresponded with the pathogenic
patterns of recurrent HSK (15).
Our data do not formally exclude an involvement for autoreactivity in
HSK. Indeed, as presented in detail elsewhere (6, 7, 8),
substantial evidence indicates that HSK lesions can be caused by HSV as
long as infected animals possess CD4+ T cells. Such T
cells, however, do not need to recognize HSV-derived antigens.
Accordingly, it was shown that DO11.10 T-cell transgenic mice
backcrossed to RAG
/
or SCID failed to mount
HSV-specific lesions (6, 7, 8) but still, unlike normal
SCIDs, expressed HSK. Similar, although less-extensive, observations
were also made in OT2xRAG1
/
mice in the present study.
Such observations make a strong case that none of the HSV proteins
provide molecular mimics to elicit HSK. However, since HSK occurs in
transgenic mice unable to generate HSV-specific T cells, the lesions
that do occur result from persisting virus in the cornea that causes
chronic proinflammatory cytokine production and the activation of
transgenic T cells (7, 8). Similarly, in the
B-cell-deficient mice the severe HSK observed likely occurred as a
consequence of persisting viral antigens in the corneal stroma. It
remains to be seen if a similar bystander activation mechanism occurs
also in normal immunocompetent mice in which virus infection of the
cornea is rapidly contained. Conceivably, HSV or an immune response to
it could damage cells and establish an autoreactive response involving
the release of sequestered self-epitopes which, in turn, sustain an
inflammatory reaction. Such a mechanism was recently proposed to occur
in coxsackie B virus-induced insulin-dependent diabetes mellitus and
dengue hemorrhagic fever (10, 24). We are currently
attempting to determine if this mechanism is involved in the
pathogenesis of HSK.
 |
ACKNOWLEDGMENTS |
We are grateful to Herbert Virgin (Washington University School
of Medicine, St. Louis, Mo.) for providing the B-cell-deficient mice.
We also thank Arvind Patel (Glasgow, United Kingdom) for the generous
gift of the vaccinia virus expressing the UL6 protein.
B.T.R. is supported by National Institutes of Health grant EY05093.
J.A.K. is supported by the Foundation Fighting Blindness, a core grant
from the National Eye Institute (P30 EYO 06360), and the Jules and
Doris Stein Professorship in Ophthalmology awarded by Research to
Prevent Blindness.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology, M409 Walters Life Sciences Bldg., University of
Tennessee, Knoxville, TN 37996-0845. Phone: (865) 974-4026. Fax: (865)
974-4007. E-mail: btr{at}utk.edu.
 |
REFERENCES |
| 1.
|
Atkinson, M. A.,
M. A. Bowman,
L. Campbell,
B. L. Darrow,
D. L. Kaufman, and N. K. Maclaren.
1994.
Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes.
J. Clin. Investig.
94:2125-2129.
|
| 2.
|
Avery, A. C.,
Z. S. Zhao,
A. Rodriguez,
E. K. Bikoff,
M. Soheilian,
C. S. Foster, and H. Cantor.
1995.
Resistance to herpes stromal keratitis conferred by an IgG2a derived peptide.
Nature
276:431-434.
|
| 3.
|
Babu, J. S.,
J. Thomas,
S. Kanangat,
L. A. Morrison,
D. M. Knipe, and B. T. Rouse.
1996.
Viral replication is required for induction of ocular immunopathology by herpes simplex virus.
J. Virol.
70:101-107[Abstract].
|
| 4.
|
Buchmeier, M. J., and T. E. Lane.
1999.
Viral induced neurodegenerative disease.
Curr. Opin. Microbiol.
2:398-402[CrossRef][Medline].
|
| 5.
|
Chun, S.,
M. Daheshia,
N. A. Kuklin, and B. T. Rouse.
1998.
Modulation of viral immunoinflammatory responses with cytokine DNA administered by different routes.
J. Virol.
72:5545-5551[Abstract/Free Full Text].
|
| 6.
|
Gangappa, S.,
J. S. Babu,
J. Thomas,
M. Daheshia, and B. T. Rouse.
1998.
Virus-induced immunoinflammatory lesions in the absence of viral antigen recognition.
J. Immunol.
161:4289-4300[Abstract/Free Full Text].
|
| 7.
|
Gangappa, S.,
S. P. Deshpande, and B. T. Rouse.
2000.
Bystander activation of CD4+ T cells can represent an exclusive means of immunopathology in a virus infection.
Eur. J. Immunol.
29:3674-3682.
|
| 8.
|
Gangappa, S.,
S. P. Deshpande, and B. T. Rouse.
2000.
Bystander activation of CD4+ T cells accounts for herpetic ocular lesions.
Investig. Opthalmol. Vis. Sci.
41:453-459[Abstract/Free Full Text].
|
| 9.
|
Horwitz, M. S.,
A. L. Cava,
C. Fine,
E. Rodriguez,
A. Ilic, and N. Sarvetnick.
2000.
Pancreatic expression of interferon protects mice from lethal coxsackie virus B3 infection and subsequent myocarditis.
Nat. Med.
6:693-697[CrossRef][Medline].
|
| 10.
|
Horwitz, M. G., and N. Sarvetnik.
1999.
Viruses, host responses and autoimmunity.
Immunol. Rev.
169:141-153.
|
| 11.
|
Horwitz, M. S.,
L. M. Bradley,
J. Harbertson,
T. Krahl,
J. Lee, and N. Sarvetnick.
1998.
Diabetes induced by coxsackie virus: initiation by bystander damage and not molecular mimicry.
Nat. Med.
4:781-785[CrossRef][Medline].
|
| 12.
|
Huber, S. A., and P. A. Lodge.
1984.
Coxssackievirus B-3 myocarditis in BALB/c mice: evidence for autoimmunity to myocyte antigens.
Am. J. Pathol.
116:21-29[Abstract].
|
| 13.
|
Kitamura, D.,
J. Roes,
R. Kuhn, and K. Rajewsky.
1991.
A B cell deficient mouse by targeted disruption of the membrane exon of the immunoglobulin µ chain gene.
Nature
250:423-427.
|
| 14.
|
Manickan, E.,
R. J. D. Rouse,
Z. Yu,
W. S. Wire, and B. T. Rouse.
1995.
Genetic immunization against herpes simplex virus. Protection is mediated by CD4 T lymphocytes.
J. Immunol.
155:259-265[Abstract].
|
| 15.
|
Margolis, T. P.,
A. R. Ellison,
L. Yang,
Y. J. Gordan, and A. V. Cevallos.
2000.
Analysis of the HSV UL6 encoding region in patients with recurrent HSV keratitis.
Investig. Opthalmol. Vis. Sci.
41:S945.
|
| 16.
|
Mercadel, C.,
D. Bouley,
D. De Staphano, and B. T. Rouse.
1993.
Herpetic stromal keratitis in the reconstituted SCID mouse model.
J. Virol.
67:3404-3408[Abstract/Free Full Text].
|
| 17.
|
Miller, S. D.,
C. L. Vanderlugt,
W. S. Begolka,
W. Pao,
R. L. Yauch,
K. L. Neville,
Y. Katz-Levy,
A. Carrizosa, and B. S. Kim.
1997.
Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading.
Nat. Med.
3:1133-1136[CrossRef][Medline].
|
| 18.
|
Nair, S.,
A. M. J. Buiting,
R. J. D. Rouse,
N. van Rosijen,
L. Huang, and B. T. Rouse.
1995.
Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses.
Int. Immunol.
7:679-688[Abstract/Free Full Text].
|
| 19.
|
Oldstone, M. B. A.
1998.
Molecular mimicry and immune-mediated diseases.
FASEB J.
12:1255-1265[Abstract/Free Full Text].
|
| 20.
|
Oldstone, M. B. A.,
M. Nerenberg,
P. Southern,
J. Price, and H. Lewicki.
1991.
Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model.
Cell
65:319-331[CrossRef][Medline].
|
| 21.
|
Opremcak, E. M.,
P. A. Wells,
P. Thompson,
J. A. Daigle,
B. A. Rice,
J. Millin, and C. S. Foster.
1988.
Immunogenetic influence of IgH-1 phenotype on experimental herpes simplex virus type-1 corneal infection.
Investig. Ophthalmol. Vis. Sci.
29:749-754[Abstract/Free Full Text].
|
| 22.
|
Robertson, J. M.,
P. E. Jensen, and B. D. Evavold.
2000.
D011.10 and OT-II T cells recognize a C-terminal ovalbumin 323-339 epitope.
J. Immunol.
164:4706-4712[Abstract/Free Full Text].
|
| 23.
|
Rose, N.
2000.
Viral damage or `molecular mimicry': placing the blame in myocarditis.
Nat. Med.
6:631-632[CrossRef][Medline].
|
| 24.
|
Rothman, A., and F. Ennis.
1999.
Immunopathogenesis of dengue hemorrhagic fever.
Virology
257:1-6[CrossRef][Medline].
|
| 25.
|
Rouse, B. T.
1996.
Virus-induced immunopathology.
Adv. Virus Res.
47:353-375[Medline].
|
| 26.
|
Rouse, B. T.,
M. Daheshia, and S. D. Schmid.
1999.
A balance of powers, p. 387-397.
In
M. Cunningham, and R. Fujinami (ed.), Effects of microbes on the immune system. The Williams & Wilkins Co., Philadelphia, Pa.
|
| 27.
|
Sercarz, E. E.,
P. V. Lehmann,
A. Ametani,
G. Benichou,
A. Miller, and K. Moudgil.
1993.
Dominance and crypticity of T cell antigenic determinants.
Annv. Rev. Immunol.
11:729-766[CrossRef][Medline].
|
| 28.
|
Shimeld, C.,
T. J. Hill,
W. A. Blyth, and D. L. Easty.
1990.
Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system.
J. Gen. Virol.
71:681-687[Abstract/Free Full Text].
|
| 29.
|
Song, B.,
J. J. Liu,
K. C. Yeh, and D. M. Knipe.
2000.
Herpes simplex virus infection blocks events in G1 phase of the cell cycle.
Virology
267:326-331[CrossRef][Medline].
|
| 30.
|
Spear, P. G., and B. Roizman.
1972.
Proteins specified by herpes simplex virus. V. Purification and structural proteins of the herpes virion.
J. Virol.
9:143-159[Abstract/Free Full Text].
|
| 31.
|
Strielein, J. W.,
M. Reza Dana, and B. R. Ksander.
1997.
Immunity causing blindness: five different paths to herpes stromal keratitis.
Immunol. Today
9:443-449.
|
| 32.
|
Tam, P. E., and R. P. Messner.
2000.
Molecular mechanisms of Coxsackie persistence in chronic inflammatory myopathy: viral RNA persists through formation of a double-stranded complex without associated genomic mutations or evolution.
J. Virol.
73:10113-10121[Abstract/Free Full Text].
|
| 33.
|
Taus, N. S.,
B Salmon, and J. D. Baines.
1998.
The herpes simplex virus 1 UL17 gene is required for localization of capsids and major and minor capsid proteins to intranuclear sites where viral DNA is cleaved and packaged.
Virology
252:115-200[CrossRef][Medline].
|
| 34.
|
Ter Meulen, V.
1988.
Autoimmune reactions against myelin basic proteins induced by corona virus and measles virus.
Ann. N. Y. Acad. Sci.
540:202-209.
|
| 35.
|
Thomas, J., and B. T. Rouse.
1998.
Immunopathology of herpetic stromal keratitis: discordance in CD4+ T cell function between euthymic host and reconstituted SCID recipients.
J. Immunol.
160:3965-3970[Abstract/Free Full Text].
|
| 36.
|
Thomas, J. T., and B. T. Rouse.
1997.
Immunopathogenesis of herpetic ocular disease.
Immunol. Res.
16/4:375[Medline].
|
| 37.
|
Verjans-George, M. G. M.,
L. Remeijer,
C. M. Mooy, and O. D. Osterhaus.
2000.
Herpes simplex virus specific T-cells infiltrate the cornea of patients with herpetic stromal keratitis (HSK): no evidence for intra-corneal autoreactive T-cells in human HSK.
Investig. Opthalmol. Vis. Sci.
41:2607-2612[Abstract/Free Full Text].
|
| 38.
|
Von Herranth, M. G., and M. B. A. Oldstone.
1996.
Virus-induced autoimmune disease.
Curr. Opin. Immunol.
8:878-885[CrossRef][Medline].
|
| 39.
|
Whitton, L. J., and R. S. Fujinami.
1999.
Viruses as triggers of autoimmunity: facts and fantasies.
Curr. Opin. Microbiol.
2:392-397[CrossRef][Medline].
|
| 40.
|
Wucherpfennig, K. W., and J. L. Strominger.
1995.
Molecular mimicry in T cell mediates autoimmunity: viral peptides activate human T cell clones specific for MBP.
Cell
80:695-705[CrossRef][Medline].
|
| 41.
|
Zhao, Z.,
F. Granucci,
L. Yeh,
P. Schaffer, and H. Cantor.
1998.
Molecular mimicry by herpes simplex virus type-1: autoimmune disease after viral infection.
Science
279:1344-1347[Abstract/Free Full Text].
|
Journal of Virology, April 2001, p. 3077-3088, Vol. 75, No. 7
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.7.3077-3088.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lundberg, P., Openshaw, H., Wang, M., Yang, H.-J., Cantin, E.
(2007). Effects of CXCR3 Signaling on Development of Fatal Encephalitis and Corneal and Periocular Skin Disease in HSV-Infected Mice Are Mouse-Strain Dependent. IOVS
48: 4162-4170
[Abstract]
[Full Text]
-
Kim, B., Suvas, S., Sarangi, P. P., Lee, S., Reisfeld, R. A., Rouse, B. T.
(2006). Vascular Endothelial Growth Factor Receptor 2-Based DNA Immunization Delays Development of Herpetic Stromal Keratitis by Antiangiogenic Effects. J. Immunol.
177: 4122-4131
[Abstract]
[Full Text]
-
Tiwari, V., Clement, C., Xu, D., Valyi-Nagy, T., Yue, B. Y. J. T., Liu, J., Shukla, D.
(2006). Role for 3-o-sulfated heparan sulfate as the receptor for herpes simplex virus type 1 entry into primary human corneal fibroblasts.. J. Virol.
80: 8970-8980
[Abstract]
[Full Text]
-
Polcicova, K., Biswas, P. S., Banerjee, K., Wisner, T. W., Rouse, B. T., Johnson, D. C.
(2005). Herpes keratitis in the absence of anterograde transport of virus from sensory ganglia to the cornea. Proc. Natl. Acad. Sci. USA
102: 11462-11467
[Abstract]
[Full Text]
-
Lang, A., Nikolich-Zugich, J.
(2005). Development and Migration of Protective CD8+ T Cells into the Nervous System following Ocular Herpes Simplex Virus-1 Infection. J. Immunol.
174: 2919-2925
[Abstract]
[Full Text]
-
Banerjee, K., Biswas, P. S., Kumaraguru, U., Schoenberger, S. P., Rouse, B. T.
(2004). Protective and Pathological Roles of Virus-Specific and Bystander CD8+ T Cells in Herpetic Stromal Keratitis. J. Immunol.
173: 7575-7583
[Abstract]
[Full Text]
-
Xu, M., Lepisto, A. J., Hendricks, R. L.
(2004). CD154 Signaling Regulates the Th1 Response to Herpes Simplex Virus-1 and Inflammation in Infected Corneas. J. Immunol.
173: 1232-1239
[Abstract]
[Full Text]
-
Seo, S. K., Park, H. Y., Choi, J. H., Kim, W. Y., Kim, Y. H., Jung, H. W., Kwon, B., Lee, H. W., Kwon, B. S.
(2003). Blocking 4-1BB/4-1BB Ligand Interactions Prevents Herpetic Stromal Keratitis. J. Immunol.
171: 576-583
[Abstract]
[Full Text]
-
Koelle, D. M., Corey, L.
(2003). Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research. Clin. Microbiol. Rev.
16: 96-113
[Abstract]
[Full Text]
-
Deshpande, S., Zheng, M., Lee, S., Banerjee, K., Gangappa, S., Kumaraguru, U., Rouse, B. T.
(2001). Bystander Activation Involving T Lymphocytes in Herpetic Stromal Keratitis. J. Immunol.
167: 2902-2910
[Abstract]
[Full Text]
-
Bachmann, M. F., Kopf, M.
(2001). On the Role of the Innate Immunity in Autoimmune Disease. JEM
193: f47-f50
[Full Text]